419571-30-5Relevant articles and documents
CYCLOPROPYLAMINE COMPOUND AS LSD1 INHIBITOR AND USE THEREOF
-
Paragraph 0207-0208; 0210, (2021/07/24)
Provided is a cyclopropylamine compound as lysine-specific demethylase 1 (LSD1) inhibitor, and a use thereof in preparation of drug for treating diseases associated with LSD1. The cyclopropylamine compound is a compound represented by formula (I), an isomer thereof, and a pharmaceutically acceptable salt thereof.
FORMULATIONS OF AN LSD1 INHIBITOR
-
, (2017/11/11)
The present application relates to pharmaceutical formulations and dosage forms of a lysine specific demethylase-1 (LSD1) inhibitor, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, including methods of preparation thereof, which are useful in the treatment of LSD1 mediated diseases such as cancer.
CCR5 antagonists: 3-(pyrrolidin-1-yl)propionic acid analogues with potent anti-HIV activity
Lynch, Christopher L.,Hale, Jeffrey J.,Budhu, Richard J.,Gentry, Amy L.,Finke, Paul E.,Caldwell, Charles G.,Mills, Sander G.,MacCoss, Malcolm,Shen, Dong-Ming,Chapman, Kevin T.,Malkowitz, Lorraine,Springer, Martin S.,Gould, Sandra L.,DeMartino, Julie A.,Siciliano, Salvatore J.,Cascierl, Margaret A.,Carella, Anthony,Carver, Gwen,Holmes, Karen,Schleif, William A.,Danzeisen, Renee,Hazuda, Daria,Kessler, Joseph,Lineberger, Janet,Miller, Michael,Emini, Emilio
, p. 2473 - 2475 (2007/10/03)
(Matrix presented) A novel approach to α,α-disubstituted-β -amino acids (β2,2-amino acids) was employed in the synthesis of a series of 3-(pyrrolidin-1-yl)-propionic acids possessing high affinity for the CCR5 receptor and potent anti-HIV activity. The rat pharmacokinetics for these new analogues featured higher bioavailabilities and lower rates of clearance as compared to cyclopentane 1.
